Search results for PX-TA1031

Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade, ProteoGenix, PX-TA1031

Description of Bamlanivimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade General information on Anti-SARS-CoV2 Spike RBD (Bamlanivimab) Monoclonal Antibody Bamlanivimab is a synthetic monoclonal antibody (mAb) that was developped from the first blood samples from COVID-19 recovered patients in the United States. Bamlanivimab is a neutralizing IgG1 mAb targetting the SARS-CoV-2 spike, which prevents the virus from entering human cells. It has been found to recognize first type and variants referenced as PX-COV-P046 and PX-COV-P052.